{'fraction_non_alphanumeric': 0.037396121883656507, 'fraction_numerical': 0.030470914127423823, 'mean_word_length': 4.878048780487805, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691–2701

We thank Violante-Cumpa et al. (1) for their comments on our article that showed metformin use in older people with type 2 diabetes (diabetes) mitigated cognitive decline and incident dementia risk (2). We here respond to each comment.

First, Violante-Cumpa et al. comment that the metformin group took other glucose-lowering medications (50%) compared with 40% in those not on metformin. While metformin is the recommended first line for treatment of diabetes, many people with diabetes …